Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a potent, long-acting ACE inhibitor with an IC50 of 4.7 nM, enabling targeted inhibition of the renin-angiotensin system in hypertension models (Tieku & Hooper, 1992). The compound is water-soluble, with a molecular weight of 441.52 g/mol, and demonstrates stability when stored desiccated at room temperature. Its mechanism involves blocking the conversion of angiotensin I to II, reducing vasoconstriction and fluid retention. APExBIO provides research-grade Lisinopril dihydrate (B3290) at ≥98% purity, confirmed by mass spectrometry and NMR. This article details its biological rationale, mechanistic benchmarks, applications, limitations, and integration into research workflows.

Biological Rationale

Lisinopril dihydrate acts as a selective inhibitor of the angiotensin converting enzyme (ACE), a zinc metallopeptidase (EC 3.4.15.1) central to the renin-angiotensin system (Tieku & Hooper, 1992). ACE catalyzes the conversion of angiotensin I, an inactive decapeptide, to angiotensin II, a potent vasoconstrictor involved in blood pressure regulation and sodium/water balance. High levels of angiotensin II are implicated in hypertension, heart failure, and renal disease. By inhibiting ACE, Lisinopril dihydrate reduces angiotensin II and aldosterone, resulting in vasodilation and decreased blood pressure. This mechanism underpins its use in preclinical and translational models of cardiovascular and renal pathology.

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate is a lysine analogue of MK 421 and functions as a competitive, reversible inhibitor of ACE (Tieku & Hooper, 1992). The compound binds the active site of ACE, chelating the catalytic zinc ion, and blocks substrate access. This leads to a marked reduction in the conversion of angiotensin I to angiotensin II. The resulting pharmacodynamic effects are:

• Decreased plasma angiotensin II concentrations
• Reduced aldosterone secretion
• Increased plasma renin activity (via negative feedback)
• Reduced peripheral vascular resistance and blood pressure

Lisinopril dihydrate is highly specific for ACE and does not significantly inhibit other zinc-dependent aminopeptidases, as confirmed by comparative enzymatic assays (Tieku & Hooper, 1992).

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an IC50 of 4.7 nM for ACE inhibition in vitro at pH 8.3 and 37°C (Tieku & Hooper, 1992, DOI).
• The compound does not inhibit aminopeptidase A (AP-A), aminopeptidase N (AP-N), or aminopeptidase W (AP-W) at concentrations up to 100 μM, supporting its selectivity (Tieku & Hooper, 1992, DOI).
• Lisinopril dihydrate is water-soluble at ≥2.46 mg/mL with gentle warming and ultrasonic treatment (APExBIO, product page).
• Storage at room temperature in a desiccated environment maintains compound stability for at least 12 months (APExBIO, product page).
• In rodent hypertension models, administration of lisinopril dihydrate led to significant reductions in systolic blood pressure within 2–4 hours post-dose (benchmark studies, internal link).

Applications, Limits & Misconceptions

Lisinopril dihydrate is extensively used in preclinical research to model:

• Hypertension and blood pressure regulation
• Heart failure and ventricular remodeling
• Acute myocardial infarction
• Diabetic nephropathy and renal protection

The compound's specificity for ACE makes it a reference standard for dissecting the renin-angiotensin system. For a detailed comparison with other ACE inhibitors in research, see this article, which Lisinopril dihydrate extends by highlighting its purity and solubility advantages.

Common Pitfalls or Misconceptions

• Not effective against non-ACE peptidases: Lisinopril dihydrate does not inhibit aminopeptidase A, N, or W, limiting its use to ACE-specific pathways (DOI).
• Insoluble in organic solvents: The compound is insoluble in ethanol and requires water, gentle warming, or ultrasonic treatment for dissolution (APExBIO).
• Degraded by long-term solution storage: Solutions are not stable for extended periods; prepare fresh for each experiment.
• Species differences: Pharmacokinetic and pharmacodynamic responses may vary between animal models and humans.
• Not suitable for non-ACE-related mechanistic studies: Use is limited to systems where ACE is the relevant pharmacological target.

Workflow Integration & Parameters

• Solubility: Dissolve Lisinopril dihydrate in water at concentrations ≥2.46 mg/mL using gentle warming and ultrasonic agitation (APExBIO).
• Storage: Store desiccated at room temperature. Avoid repeated freeze-thaw cycles and prolonged solution storage.
• Purity and QC: APExBIO's B3290 lot is ≥98% pure, with batch-specific mass spectrometry and NMR profiles available (product page).
• Dosing: Typical in vivo doses range from 1–10 mg/kg in rodents; adjust for species and experimental design (internal resource). This article updates previous dosing guidelines with solubility best practices.
• Shipping: Shipped on blue ice for small molecule stability.

For advanced mechanistic and translational strategies using Lisinopril dihydrate, see this mechanistic review. This article adds current evidence on selectivity and workflow optimization.

Conclusion & Outlook

Lisinopril dihydrate is a validated, research-grade, long-acting ACE inhibitor with superior selectivity and solubility. Its robust inhibition of the renin-angiotensin system underpins its value in hypertension, heart failure, and nephropathy research. APExBIO provides high-purity Lisinopril dihydrate (B3290), supporting experimental rigor and reproducibility. Future studies may expand use cases as new insights into ACE-related pathways and translational models emerge.

For detailed protocols and batch-specific QC, refer to the Lisinopril dihydrate product page.